Herbo-mineral formulation for the treatment of cardio vascular diseases and method of preparation thereof

Abstract

Herbo-mineral Formulation for the treatment of Cardio vascular diseases and method of preparing the same are disclosed herein. The disclosed herbo-mineral formulation includes herb and mineral components which facilitate in treating Cardio vascular diseases. Cardio vascular diseases may include any condition associated with heart and blood vessels. Further, the disclosed formulation may also be instrumental as anti-oxidating, anti-stress, hypolipidemic, atherogenic, antihypertensive, apoptotsis inhibiting and cardio-protective agent.

We claim: 
     
         1 . A formulation for treatment and management of Cardiovascular ailments comprising:
 a herb component comprising  Terminalia arjuna, Sida rombifolia, Withania somnifera, Tinospora cordifolia, Punica granatum, Emblica officinalis  and  Commiphora mukul , or their extracts thereof; and   a mineral component comprising shilajit and bhasma.   
     
     
         2 . The formulation claimed in  claim 1 , wherein  Terminalia arjuna  is present in an amount ranging from 8 to 12 wt %,  Sida rombifolia  is present in an amount ranging from 2 to 6 wt %,  Withania somnifera  is present in an amount ranging from 2 to 6 wt %,  Tinospora cordifolia  is present in an amount ranging from 2 to 6 wt %,  Punica granatum  is present in an amount ranging from 2 to 6 wt %,  Emblica officinalis  is present in an amount ranging from 2 to 6 wt % and  Commiphora mukul  is present in an amount ranging from 2 to 6 wt %. 
     
     
         3 . The formulation claimed in  claim 1  wherein said herb component further comprises of atleast one herb selected from a group consisting of  Embelia ribes, Rubia cordifolia, Nardostachys jatamansi, Terminalia chebula, Terminalia bellerica, Piper longum, Piper nigrum, Zingiber officinalis, Boerhavia diffusa, Bamboo manna, Madhuka indica, Azhadirachta indica, Picrorhiza kurroa, Holy basil, Steriospermum suaveolens, Premna mucronata, Gmelina arborea, Aegle marmelos, Oroxylum indicum, Desmodium gangeticum, Uraria pieta, Solanum indicum, Solanum xanthocarpum , and  Tribulus terrestris ; or their extracts thereof. 
     
     
         4 . The formulation as claimed in  claim 3 , wherein said herb is present in an amount of ≤4 wt %. 
     
     
         5 . The formulation as claimed in  claim 1 , wherein said mineral component comprises of atleast one bhasma selected from a group consisting of Muktasukti bhasma, Loha bhasma, Abhraka bhasma, Swarnamaksika bhasma and Pravala bhasma. 
     
     
         6 . The formulation as claimed in  claim 1 , wherein shilajit is present in an amount ranging from 1 to 3 wt %. 
     
     
         7 . The formulation as claimed in  claim 5 , wherein Muktasukti bhasma is present in an amount of ≤2 wt %, Loha bhasma is present in an amount of ≤2 wt %, Abhraka bhasma is present in an amount of ≤3 wt %, Swarnamaksika bhasma is present in an amount of ≤2 wt % and Pravala bhasma is present in an amount of ≤2 wt %. 
     
     
         8 . The formulation as claimed in  claim 1 , further comprising a suitable excipient, preferably gum acacia. 
     
     
         9 . The formulation as claimed in  claim 1 , wherein said formulation is in the form of powder. 
     
     
         10 . The formulation as claimed in  claim 1 , wherein said formulation is in the form of tablet. 
     
     
         11 . The formulation as claimed in  claim 10 , wherein said tablet is in the form of 500 mg tablets. 
     
     
         12 . Use of the formulation as claimed in  claim 1  in the preparation of a medicament for treating and preventing Cardiovascular diseases. 
     
     
         13 . Use of the formulation as claimed in  claim 1  in the preparation of a medicament for reducing the risks of Cardiovascular diseases. 
     
     
         14 . A process for the preparation of formulation claimed in  claim 1 , comprising:
 levigating bhasmas and shilajit;   adding finely powdered herbs; and   adding grinding decoction while continuing grinding to obtain a ground mass.   
     
     
         15 . The process for the preparation of a formulation as claimed in  claim 14 , wherein said bhasmas are selected from a group consisting of Muktasukti bhasma, Loha bhasma, Abhraka bhasma, Swarnamaksika bhasma and Pravala bhasma. 
     
     
         16 . The process for the preparation of a formulation as claimed in  claim 14 , wherein said finely powdered herbs comprises of finely powdered form of:  Terminalia arjuna  (dry stem bark),  Sida rombifolia  (dry root),  Withania somnifera (dry root),  Rubia cordifolia (dry root),  Nardostachys jatamansi (dry root),  Boerhavia diffusa (dry root),  Picrorhiza kurroa (dry root),  Steriospermum suaveolens (dry root),  Premna mucronata (dry root),  Gmelina arborea (dry root),  Aegle marmelos (dry root),  Oroxylum indicum (dry root),  Solanum indicum  (dry root),  Embelia ribes  (dry fruit),  Emblica officinalis  (dry fruit),  Terminalia chebula (dry fruit),  Terminalia bellerica (dry fruit),  Piper longum (dry fruit),  Piper nigrum (dry fruit),  Tribulus terrestris (dry fruit),  Azhadirachta indica  (dry bark),  Solanum xanthocarpum  (dry plant),  Uraria picta (dry plant),  Desmodium gangeticum  (dry plant),  Tinospora cordifolia  (dry stem),  Punica granatum  (dry fruit pericarp),  Zingiber officinalis  (dry rhizome),  Bamboo manna (exudate),  Madhuka indica  (dry flower),  Holy basil  (dry leaves) and  Commiphora mukul  (gum resin). 
     
     
         17 . The process for the preparation of a formulation as claimed in  claim 14 , wherein said grinding decoction is a decoction of atleast one herb selected from the group consisting of  Terminalia arjuna, Asparagus racemosus, Asafetida, Cuminum cyminum, Plumbago rosea, Baliospermum montanum, Ocimum sanctum, Aloevera, Plantago ovata, Steriospermum suaveolens, Premna mucronata, Gmelina arborea, Aegle marmelos, Oroxylum indicum, Desmodium gangeticum, Uraria picta, Solanum indicum, Solanum xanthocarpum  and  Tribulus terrestris.    
     
     
         18 . A method of reducing the risks of Cardiovascular diseases comprising, administering a therapeutically effective amount of the formulation claimed in  claim 1 . 
     
     
         19 . A method of treating and preventing Cardiovascular diseases comprising, administering a therapeutically effective amount of the formulation claimed in  claim 1 . 
     
     
         20 . The method of treating and preventing Cardiovascular diseases as claimed in  claim 19 , wherein said formulation is preferably administered at a dose of two 500 mg tablets twice a day. 
     
     
         21 . A method of treating and preventing Cardiovascular diseases comprising administering a therapeutically effective amount of the formulation claimed in  claim 1 . 
     
     
         22 . The method of treating and preventing Cardiovascular diseases as claimed in  claim 19 , wherein said therapeutically effective amount is 500 to 1000 mg administered one to three times a day. 
     
     
         23 . The method of treating/preventing Cardiovascular diseases as claimed in  claim 19 , wherein said formulation is administered along with administration of at least one other medication prescribed for treatment of Cardiovascular diseases.